DX07  Patient-Reported Outcomes After Fingolimod Switch: Early Consistent Benefit
Mark Cascione, Neetu Agashivala, Stanley Li, Luigi M. Barbato, Edward Kim

DX08  Treatment Selection in Multiple Sclerosis: Results of a Physician Survey
Kristin A. Hanson, Neetu Agashivala, Karina Raimundo, Edward Kim, Sonja M. Stringer, Zaneta Balanta

DX09  Fingolimod Efficacy and Safety vs. Placebo: Phase 3 FREEDOMS II Study
Mark Agius, Douglas Jeffery, Xiangyi Meng, Ron Hashmonay, Allitia DiBernardo

DX10  25-Hydroxyvitamin D and Multiple Sclerosis Activity During Therapy with Interferon Beta-1b
Alberto Ascherio, Kassandra Munger, Claire Simon, Ludwig Kappos, Chris H. Polman, Mark Freedman,

DX11  Use of ACTHar Gel for Multiple Sclerosis Exacerbations During Natalizumab
Ronald O. Bailey, Randy R. Heim, Vu A. Nguyen, Carina G. Sprague

DX12  Natalizumab in Anti-JCV Seronegative Patients with Early Multiple Sclerosis
Roumen Balabanov, Jai Perumal, Robert J. Fox, Denise Campagnolo, Emese Dian, Stefan Lanker, Jenny

DX13  A Comparison of Two Health-Related Quality of Life Measures in Pediatric D
Austin Sye, E. Ann Yeh, Brenda Banwell, Christine Till

DX14  Preventing New Enhancing Lesions and Relapses After Discontinuing Tysabri
Tina Butterfield, Victor A. Maquera

DX15  Peginterferon Beta-1a via Autoinjector in Relapsing Multiple Sclerosis
Peter A. Calabresi, Serena Hung, Ali Seddighzadeh, Shifang Liu, Bjorn Sperling, Aaron Deykin

DX16  New Measures of Neurologic Disability Derived from NARCOMS Registry Data
Eric Chamot, Ilya Kister, Gary Cutter

DX17  Early Effect of Fingolimod on Clinical and MRI Outcomes in Relapsing Multiple Sclerosis
Peter Chin, Xiangyi Meng, Ron Hashmonay

DX18  Depression, Fatigue, and Clinical Improvements After Switch to Fingolimod
Mark Agius, Edward Kim, Stanley Li, Peter Chin, Ron Hashmonay, Neetu Agashivala

DX19  Joint Commission Disease-Specific Care Certification Process for Multiple Sclerosis
Jill M. Conway, Lindsey Belt, Michael Kaufman, Linda Moore, Marie Moore, Marlow Price, Lisa Smart, Diana

DX20  Improved Quality of Life After Therapy Change to Fingolimod
Heidi Crayton, Samuel F. Hunter, Cynthia Huffman, Neetu Agashivala, Lesley Schofield, Kevin McCague, Anna

DX21  Alemtuzumab’s Effects on Disability Outcomes Occur Early in Care-MS II
Heidi Crayton, Douglas L. Arnold, Jeffrey A. Cohen, Alasdair J. Coles, Christian Confavreux, Edward J. Fox, John,

DX22  Novel Model of Care for the Person with Multiple Sclerosis
Allyn A. Danni

DX23  Multiple Sclerosis Patients Using RebiSmart™ Maintain Good Treatment Adherence
Virginia Devonshire, Anthony Feinstein, Patrick Moriarty

DX24  Case Series of Cardiac Complications During Fingolimod First Dose Observation
Elizabeth M. R. Dragan, George J. Hutton, Yochai Birnbaum

DX25  Neuromyelitis Optica Presenting as Multiple Sclerosis Worsening on Natalizumab
Elizabeth M. R. Dragan, George J. Hutton

DX26  Efficacy of Fingolimod in Ethnic Minorities
Elizabeth M. R. Dragan, Toni Saldana-King, George J. Hutton

DX27  Patient-Reported Experience Measures and Outcomes in Multiple Sclerosis
Nikki Embrey, Delyth Thomas, Laura Parkes

DX28  Predictors of Successful Acceptance of Home Telemanagement in Multiple Sclerosis
Joseph Finkelstein, Eunme Cha, Mitchell T. Wallin

DX29  Treatment Satisfaction and Clinical Improvement After Switch to Fingolimod
Edward Fox, Keith Edwards, J. Gordon Burch, Edward Kim, Linda Pestreich, Kevin McCague, Luigi M. Barbato
First Case of Immune Thrombocytopenia in the CAMPATH Extension Trial (CAMMS03409)
Malcolm H. Gottesman, Shicong Ye, John Delmonte Jr., Abigail McNall, Kimberly Byrnes, Eileen Boylan, Denise Cheng

Data Management and Monitoring in the CombiRx Randomized Trial
Tarah Gustafson, C. Steve Powell, Amber Salter, Jing Wang, Fred D. Lublin, Jerry Wolinsky, Robin Comité

Prolonged Enhancement of a Demyelinating Lesion Mimicking Lymphoma
Paula Hardeman, Elliot Frohman, Benjamin Greenberg

Values and Challenges of Multiple Sclerosis Specialist Certification
Elsie E. Gulick

Study Design of a Multinational Gilenya™ (Fingolimod) Pregnancy Exposure Registry
Yvonne Geissbuehler, Estel Plana Hortoneda, Ron Hashmonay, Simrat Randhawa

Cardiac Effects of Fingolimod in Patients with Multiple Sclerosis
Bruce L. Hughes, Mark Cascione, Kevin McCague, Linda Pestreich, Lesley Schofield, Edward Kim, Luigi A. Ferrante, Jerry Wolinsky, Robin Comité

Patient on Natalizumab for Multiple Sclerosis: Earworms or Musical Hallucinations?
Farhat Husain, Jeremy Levin, Cecilie Fjeldstad

Durable Effects of Alemtuzumab on Relapse Rate over Time in Studies of Relapsing-Remitting Multiple Sclerosis
Douglas Jeffery, Jeffrey A. Cohen, Xiangyi Meng, Ron Hashmonay

Pregnancy Outcomes with Teriflunomide: Female Patients and Partners of Male Patients
Lily Jung Henson, Olaf Stuve, Myriam Benamor, Sandrine Turpault, Françoise Menguy-Vacheron

Time Course of Treatment Effects of BG-12 (Dimethyl Fumarate) in Multiple Sclerosis

Efficacy of Glatiramer Acetate 40-mg Injection Three Times Weekly
Omar Khan, Peter Reckmann, Alexey Boyko, Krzysztof Selmaj, Robert Zvadinov

Prospective, Longitudinal Study of Natalizumab Treatment in Multiple Sclerosis
Ellen Lathi

Patient-Reported Outcomes in Primary Progressive Multiple Sclerosis
Grace E. Little, Kesav Raghavan, Brian C. Healy, David J. Rintell, Howard L. Weiner, Tanuja Chitnis, Bo M. O'Connor

Considerations for Implementing a Health and Wellness Program for People with Multiple Sclerosis
Christine Manella, Deborah Backus, Blake Burdette

CCSVI Treatment and Comorbidity: A Province-Wide Study of Multiple Sclerosis
Ruth Ann Marrie, Luanne Metz, Katayoun Alikhani, Gregg Blevins, Jacqueline Bakker, Larry Svenson, Nives Vitali, Frank DeSelm

Best Practice for Education and Ongoing Evaluation of Patients on Gilenya and Monoclonal Antibodies
Sarah M. Militello

Combination Interferon Beta-1a and Mycophenolate Mofetil in Relapsing-Remitting Multiple Sclerosis
Jacqueline A. Nicholas, Yuhong Yang, Caroline Schaffer, Morgan Savel, Kyle Porter, Claudia Kirsch, Michael B. Campion

Implementation of a Quality Improvement Program in a Multiple Sclerosis Clinic
Margie O'Leary, Rock Heyman, Ryan Orie, Galen Mitchell, Islam Zaydan, Rebecca Rosiek, Victoria Youn

Effect of BG-12 (Dimethyl Fumarate) in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis Patients
J. Theodore Phillips, Ralf Gold, Gavin Giovannoni, Robert J. Fox, Annie Zhang, Leslie Meltzer, Nuwan C. Kurukulasuriya

Cardiac Effects of Fingolimod: First-Dose Observation
Simrat Randhawa, Xiangyi Meng, Ron Hashmonay

JC Virus Antibody Index Stratifies PML Risk in Natalizumab-Treated Multiple Sclerosis Patients
Tatiana Plavina, Meena Subramanyam, Gary Bloomgren, Sandra Richman, Amy Pace, Sophia Lee, Brian Hsia, Ray S. B. Kwong, Stephen L. Lake, David H. Margolin, Michael A. Panzara, Alastair Compston

BG-12 (Dimethyl Fumarate) with Aspirin Pretreatment or Slow Dose Titration
Heidy Russell, John O’Gorman, Jie Li, Glenn Phillips, Vissia Viglietta
DX53  Persistence and Treatment Satisfaction in Patients Using the AVONEX PEN
   Bjorn Sperling, Sergio Slawka, Christina Ghaus, Xiaojun You

DX54  Switching to Fingolimod or Interferon Beta-1a: A Cost-Effectiveness Analysis
   Kangho Suh, Neetu Agashivala, Edward Kim

DX55  Long-Term Safety and Tolerability of Fingolimod in Relapsing-Remitting Multiple Sclerosis
   Reinhard Hohlfeld, Xiangyi Meng, Ron Hashmonay, Nadia Tenenbaum

DX56  Predictors of Switching First-Line Disease-Modifying Therapy for Multiple Sclerosis
   Barbara E. Teter, Neetu Agashivala, Katelyn S. Kavak, Lynn Chouhfeh, Ron Hashmonay, Bianca Weinstock-Guttman

DX57  Development of a Care Pathway for Patients with Suspected PML
   Karen Vernon, William Lusher, Fran Jackson, David Rog

DX58  Teriflunomide in Routine Clinical Practice: Design of the Teri-PRO Study
   Timothy L. Vollmer, Aline Stalla-Bourdillon, Miqun Robinson

DX59  Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire: Pilot Study
   Alona Williamson, Tracy Flemming Tracy, Jennifer Smrtka, Carol Saunders, Constance B. Easterling, Amy Perrin Ross

DX60  Herpes Infection Risk Reduced with Acyclovir Prophylaxis After Alemtuzumab

DX61  High Monthly T2 Lesion Burden Associated with Improved EDSS Score upon Starting Multiple Sclerosis Treatment
   Charles C. Yu, Samantha Lancia, Nhial Tutlam, Junqian Xu, Robert T. Naismith

DX62  Measuring Adherence of Tecfidera®
   Lise Casady, Angela M. Aungst, Derrick S. Robertson, Sean M. Masi

DX63  Rescaling the EDSS Using Rasch Analysis
   William J. Culpepper II, Mitchell T. Wallin